Clovis Oncology Announces Second U.S. Patent Issued in Rucaparib High Dosage Strength Tablet Patent Family with Expiration in 2035
November 20, 2018
• Claims cover methods of treating cancer with all commercial dosage
strengths of Rubraca®
• This will be the 11th Orange Book-listed patent for Rubraca
BOULDER, Colo.–(BUSINESS WIRE)–Clovis
Oncology, Inc. (NASDAQ:CLVS) announced today that the United States
Patent and Trademark Office issued United States Patent 10,130,636 with
claims directed to methods of treating cancer with high dosage strength
rucaparib camsylate formulations. The patent claims cover methods of
treating cancer with commercial Rubraca product, including all
commercial dosage strengths (200, 250 and 300mg). The high dosage
strength rucaparib formulation patent expires in 2035, and will join
multiple patents directed to rucaparib, rucaparib camsylate, and methods
of treatment as the 11th Orange Book-listed patent for rucaparib.
“We have multiple families of patents protecting Rubraca in the U.S.,
including composition of matter, salts/polymorphs, dosage forms and
formulations, and methods of use, and we continue to add new patents,
including this high dosage strength method of treatment patent,” said
Patrick J. Mahaffy, President and CEO of Clovis Oncology. “Each
additional patent provides further protection for Rubraca, and this is
relevant not only to our current indications in ovarian cancer, but also
to multiple potential additional indications based on our ongoing and
substantial clinical development programs.”
About Rubraca® (rucaparib)
Rubraca is an oral, small molecule inhibitor of PARP1, PARP2 and PARP3
being developed in multiple tumor types, including ovarian, metastatic
castration-resistant prostate, and bladder cancers, as monotherapy, and
in combination with other anti-cancer agents. Exploratory studies in
other tumor types are also underway. Clovis holds worldwide rights for
Rubraca. Rubraca is an unlicensed medical product outside of the U.S.
and Europe.
About Clovis Oncology
Clovis Oncology, Inc. is a biopharmaceutical company focused on
acquiring, developing and commercializing innovative anti-cancer agents
in the U.S., Europe and additional international markets. Clovis
Oncology targets development programs at specific subsets of cancer
populations, and simultaneously develops, with partners, diagnostic
tools intended to direct a compound in development to the population
that is most likely to benefit from its use. Clovis Oncology is
headquartered in Boulder, Colorado, and has additional offices in San
Francisco and Oakland, California and Cambridge, UK. Please visit clovisoncology.com
for more information.
To the extent that statements contained in this press release are not
descriptions of historical facts regarding Clovis Oncology, they are
forward-looking statements reflecting the current beliefs and
expectations of management. Examples of forward-looking statements
contained in this press release include, among others, statements
regarding our expectation of the expiration of and the coverage provided
by certain patents in our portfolio. Such forward-looking statements
involve substantial risks and uncertainties that could cause our future
results, performance or achievements to differ significantly from that
expressed or implied by the forward-looking statements. Such risks and
uncertainties include, among others, the uncertainties inherent in the
actions by the United States Patent and Trademark Office and third-party
challenges to the validity, enforceability or scope of our patents.
Clovis Oncology does not undertake to update or revise any
forward-looking statements. A further description of risks and
uncertainties can be found in Clovis Oncology’s filings with the
Securities and Exchange Commission, including its Annual Report on Form
10-K and its reports on Form 10-Q and Form 8-K.
Contacts
Clovis Oncology
Breanna Burkart
303.625.5023
bburkart@clovisoncology.com
or
Anna
Sussman
303.625.5022
asussman@clovisoncology.com